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Effect of RU 38486 on TNF production and toxicity 
George Lkilr Jr.‘, Em6 Dudab and George Lakaif 
Glurocorticoid stctoids provide conridcrithlc protection against the systemic toxicity of tumor nccrorir fnctore (TNF-a, cuchcxin). In animal 
cxpcrimcnts RU 38486 (mifcpristonc). u steroid mttigonist. increased rhc synthesis cf TNF und sensitized the aninuls IO thccytotonic action of 
TNF. As compared to the control und mcthylprcdnisola~ttWcd groups, mlfcprirtonc signinuntly increased the lcvcl of TNF in the scorn. liver 
and rplccn of lipopolysacchuridc (LPS).trcatcd ;Inimalr In tissue cultures F.11 38486 induced rhc TNF synthesis of mycloid cells nnd incrcascd the 
TNP production of gcnctisally modified H&a cclk. which synthclrizc TNF constitutk:y. Normul nnd tumor ccl1 cultures cxhibitcd incrcascd 
sensitivity toward TNF in the presensc of mtitipt&onc. 
Tumor nccrosir ktors: RU 3X486; Mifrpristonc: Endcrtoxin: Cilucosorticoid 
1, INTRODUCTION 
Tumor necrosis factor (TNF) shows a very high spcc- 
if’lti:y in its cytotoxicity towards ccrtnin tumor cells [l]. 
At the same time, TNF is a lymphokinc with powerful 
immunostimulating effects and causes evere systemic 
conscqucnccs ut elcvatcd lcvcls [2]. Furthermore, TNF 
[3.4] and other cytokincs [5] hnvc been also implicated 
in the pothogcncsis of septic shock, which is one of the 
most common causes of death in intensive care units 
today. 
Despite advances in technology and in antibiotic 
therapy, the mortality rate for septic shock remains in 
excess of 50% [6,7]. Glucocorticoid hormones arc 
krlown to protect cxgcrimcntal animals very cffcctivcly 
against he lethal effect of bacterial cndotoxins [a], but 
the bcncficial influcncc of these hormones in clinical and 
cxpcrimcntol fomls of septic shock remains a question 
of d&ate [9-l I]. Antagonists of steroid hormones pro- 
vide ;t new framework of action not only because they 
arc of potential clinical USC, but more so bccausc they 
pcrmh molecular dissection of hormone-dependent 
proc&scs. 
Tier antiglucocorticoid action of mifcpristonc, or RU 
38486, has been reviewed elsewhere [12,13], In earlier 
studier, WC have shown that this glucocorticoid antago- 
nist scnsitizcs both Swiss albino OF1 and endotoxin 
low-responder, C3H!HcJ mite to cndotoxin lethality 
[Is]. WC have also shown that RU 38486 sensitizes en- 
dotoxin.tolcrant (cndotoxin-pretreated) and normal 
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mice to the lethal cffcct of septic and cndotoxin shock 
[15.16]. 
Tumor necrosis factor-a is the primary mediator of 
the pathogcncsis of cndotoxin and scptic shock [17.18]. 
Glucocorticoids inhibit LDS.induced TNF production 
[19] and TNF can stimulate pituitary adrcnocorti- 
cotropin secretion, resulting in the rclcasc of corticostcr- 
one [20,:!1]. All thcsc findings suggest an important role 
of the ncurocndocrinc axis in the secretion of steroid 
hormones and in the modulation of cytokinc produc- 
tion. On this basis, WC set out to study the influence of 
RU 38486 on TNF production and toxicity. 
2. MATERIALS AND METHODS 
Mnlc NMRI mice (LAW Animal HOW. CiBd6llb, Hungary). 
30-35 g in weight. wcrc housed with free xccss IO pcllct food und 
wiltcr ut all times. 
2.2, Chwricab 
Mifcpristonc. RU 38486. was from Rousscl~Ucl~f. Fruncc Tt wns 
incorporated into phospholipid liporomcs. Multilrmcllrmr liposomcs 
wcrc prepared from phosphatidylcholinc (Sigma) and cholaterol 
(Sigma) according to :hc method drrrrib-d carlicr [22]. 
Mcthylprcdnirnlonc (Orion. Fintad) arid RU 38486 wcrc injcctcd 
intravenously just before the lipopolysaccharidc(LPS) trcalmcnt. & 
chrrirltiu cob 026B6 lipopolysaccharidc (Difso, lot no. 672736) was 
susgcudcd in isotonic. nonpyrogcnic saline. 
2.3. ClotGlg rend praducriott o/ ltutior necrosis /hctnr 
TNF-a (human tumor nccroris factor-e, cachcxin) gcnc was iso- 
lotcd from a human gcnc library. The MspI-EcuRI fragmcnl, coding 
for approx. 80% of the fourth cxon of rhc TNF gent was li&Wd wirh 
a 102 bp synthetic oligonwlcotidc coding for the missing Nwtninal 
pnrt of the mature prokin. The multingconstruct wascloncd into the 
k?urtM lritc of tlrc cxprcssion vcclor pDRS40 (Pharmaciu Fin.? C$rm. 
icnls). 
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B <u/i tcllx h&wing the ubwc plasmid produce tipprox. I my 
rce4TNF per liter culture iT yruwn in LB medium until the wrly 
stutionury phm (Mui cl al.. mnnu#ript in prCp.1. 
2.4. A~riljrrr~ivrr ~ml trxxf~,b* uf htmr rrzcrur~~ favar 
Rccombinnnt TNF ws purifiid by II combinirtion of ttmmonium 
sulfiltc prccipitatian. cdntrollcd pore ylae and hydrophobic intcnc- 
tion chronr~tayruphicr and FPLC (Mei ct ;II., mrnuscript in prep.). 
If ncwsury. the lrrl t~ccs of LPS wccc removed by affinity chrome- 
togmphy Gn pblymyxin B.u&uQsc. The tlnnl product yicldcd n ringlc 
clcctfophorctic b;rnd of approx. 17 kD& w&P ut !c;r%t 95% pure b% 
dcrrrmiwd by silver staining of SDS~palyturylamidc #clr;l, hd a WC- 
cik uctivity of et leerit 10 millian Ulmg nnd contlrin4 Its* thun 
0. I?5 U ofcndotoxin per mg protein (mtisurcd by the LAL-Pyro&cnt 
nssay. Wittakcr 8ioproductr Wmtkcrrvillc. MD). 
L929 ccllr wrc srown in DMEM (Scrw, Hcidclberp) with 59 
serum. Supcrnutank alzsaycd for ~hc prarnrc 0f YNF wcrc cxlnct~d 
with chloroform to rcmovc KU 384i186 bclorc ditilyrir and conccntm- 
tian. 
Uiosuny uf TNP WUL bnscd on its cyto\oxirity. mcnrurcd on mow 
LX9 tumor rcllr. in the presence of I &ml actin0mycin-0. al cxnClly 
37% [ 1,231. The TNF srsritivity of normni mow 3T3 rcllr ws 
nwycd In the prcscncc oTO.IZS and Cl.ZS~a/ml tictittomycin-0. These 
cells tolcrntcd up IO IO,000 U TNF tit 37*C, in the ubscncc or mifc- 
prirlonc. 
Killing of cells WIT trrscsscd viu the uptukc of Ncu~ral red vlt;rl dye. 
The um0unt of TNF rcquircd t0 mcdilrtc the half-muxim;ll cytotox- 
icily CI~ L9Z9 cells +bw rniyncd ;I value br I U [1.?3]. 
The tirstic tlivcr. rplccn) wrsminccd nnd wnicatcd. nnd mtrnbrirnrr 
wcrc pcllelcd by ccntrit’ugiltiun and rcsurpcndcd by brick roniwion. 
TPIF WIIP tittred in both the sapcrnatent and mcmbrunc fractions. 
BZlfB moue mycloid tumor cells and TNF.producing M9 human 
cpithclial tumor cells (dcriv;nivcs or HcLa cells) wcrc grown in 
DMEM with 5% %crum, PZX8 ccllx da nat product TNF unlcu ztcti- 
vated by the prcscncc ol* cndotoxin or cxogcnourly rddcd TNF. M9 
cells harbw a DNA conurusi conttrining the human TNF-0 ycnc 
under the control of the SVllO cnhwccr. und thercforc express TNF 
c0nstitut ‘xty. ut high Icvcl. 
The comp&lranr of the mcllns uiIcr an;rlyrix or vwhncc wcrc car- 
ried out hy the mclhad orSchcffc. Stutisti~l xiynificuncc WI& acrcptcd 
iit P c Wl5. SurVivill dllte wcrc ;rnulyrcd for ~!ntistlcnl riynifcnncc by 
the Pishcr CXUCI test. 
3. REFULTS 
RU 384%d greatly increased the toxicity of hTNF 
both in tissue cultures and in animals. The highly scnsi- 
tivc mouse L919 tumor cells wcrc killed by a 2-3 times 
lower TNF concentration, if RU 38486 was nlso prcs- 
cnt. 3T3 normal mouss fibroblast. which is highly rcsis- 
tant to TNF, bccamc sensitive in the prcscncc of the 
drug (Fig. 1). Intravenous injection of 2 ,ug/lO g body 
weight of hT.NF. concurrently with 1 pg& body weight 
of LPS killed 4 of 20 animals (80% survival). but when 
it wus supplcmcntcd with RU 38486 trcatmcnt (1 mg) 
ull of the 20 animnb died (Table I). lnjcction of mcth- 
ylprcdnisolonc (2 mg) concurrently with hTNF + LPS 
+ RU rcsultcd in significant protection (70% survival). 
It Wi\s earlier shown that bacterial cndotoxin potcnti- 
atcs the toxicity of TNF 124). so that the vimultnncous 
prcscncc of othcrwisc innocuous amounts of LPS nnd 
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Fig. I. The cffcct of RU 3W116 on the TNF-ssnritivity of 3T3 cells. 
Mouse 3T3 nermrl fibroblustr were prow on microtircr plutw The 
cultures wrc trwtcd with liporomcs or liporomccntrappcd mifcpris- 
tone (40 rumI) before the cwporurc to diffcrcnt conccntntionr UT 
TNF, 0.125 or O.?S p&/ml uctinomycln-D ws added to purilllcl GUI- 
turds. (A) O-,75 p@nl actinomycin-D + RU: (0) O.llS ~,#ml nctinomy- 
tin-D + RU; (4 O.?StiNrnl uctinomycin-D; (0) 0.1 ZS&W nclinomy- 
tin-0. 
TNF triggers lethal shock. In our cxpsrimsnts, TFN + 
RU gave 70% survival. but if combinsd with LPS trci\t- 
mcnt, the survival dropped to 0% 
The cffcct of RU 38486 was not lirnitcd to the in- 
creased TNF sensitivity of cultured cells and animals. 
The &err of the drug ott TNF production wns ulso 
dcmonstratsd in vitro. In M9 cslls, which product 
hTNF (as B rssult of genetic tmnsformation with the 
hTNF gcnc). the TNF synthesis mtc was more thun 
doubled as XI rcvult of RU 38486 treatment (Fig. 2). In 
mouss P388 myc!;id tumor cells the regulation of the 
Fig. 1. The clkct ol*RU 3Wd on thcTNF production of M9innd P388 
ccllr. The cells wrc gown in DMEM. TNT: W:IS wlluctcd from lhc 
medium tind litcrcd ils dncrihcd in Methods. TilL: figure ~IIOWS daily 
production of co~Qlusnt culturcr. IO@ cell/ml. 0 = M9 cclla, grown 
wilhoul mikprisIonc: I. ? illld 3 = ML) cells. grown in the prcrcncc of 
6. ?O ;rnd 6U yylml mifcpristonc. rcqxclivcly. PZS# CCIIS wccc ~I*OWI 
in ~hc iIbsrllcc (4) ;~nd the prcxcncc (5) ol’ 4) jt@lll nriltpristonr. 
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Fig. 3. Thr: effect af RU 3148Gan the cndotoxin-induced TNF prodw 
tion in the blood (A), liver (13) ;rnd spleen (C). hninr;da wcrc givrn 
liporonm a!onc, RU M&b (I mg). rnctlrylprcdl~iMlonc (MB) (1 my) 
or RU 3&4kiB (RU) + MP intwvcnously just bcforc tltc cndotoxin 
challcn~,c (1p&g). TNF ~ctiwity WY mcasmd 1, 1. 3 md 4 h ;litcr 
1 PS trcittnmt. Mcunli of results on 10 mice per group. 
TNF-a gcnc wns unbred. Them cells did not prods 
TNF without induction by LPS, TNF or phorbol cstcrs. 
The prcscncc of RU 38486 ;~!onc induced the synthesis 
of rclntivcly high amounts ofTNF in thcscculturcs. The 
cffcct of RU 38486 on the rutc of LPS-in&cd TNF 
production in the swum, liver and spleen is shown in 
Fig, 3A,B,C, At the time of pc& rcsponsc (one hour 
after LPS injection) RU 38486 had significtmtly in- 
crwcd the conccntmtion of TNF in the swum. liver 
und spleen OS compurcd to the control or mcthylprcdni- 
solonc-trcptcd groups. Mcthylprednisolonc sign& 
cuntly decreased LPS-induced TNF production and 
completely abolished the effect of RU 38486. Neither 
RU 38486 nor mcrhylprcdnisolonc indused TNF pro- 
duction (data not shown). 
4. DISCUSSION 
TNF.a (cuchcctin) is il mucrophugedcrivcd peptids 
hormone rclcoscd in response to different stimuli. in= 
eluding bacteria! LPS. It has !xcn implicated as u prin. 
ciptl! mediator in septic and cndotoain shock. Scvcrrrl 
lines of cvidcncc huvc so f;lr indicatsd that the pituitary- 
;rdrcnal axis !~trs un important part in regulating the 
TNF activity. Adrcnalcctomy sensitizes mice to the !c= 
tha! cffcct of TNF. snd that sensitization is abolished 
;lftcr addition of dcxamcthnsonc [251. Furthcrrnorc, in 
udrcnalcctomizcd or hypophyscctomkd mice the LPS- 
induced serum TNF conccntmtion rennin5 tit a high 
lcvcl as compnrcd to normal animals (211. In in vitro 
models. glucocorticoids inhibit the synthesis of TNF 
and another important septic shock mediator. IL-I. at 
t!lc !cvc!s of both transcription and tmnslution 
[ !9.26,27]. Morcovcr. in cxpcrimcntal animals dcxam- 
cth;lsonc protects against Icth;llity induced by TNF [28]. 
Our results prove that RU 38486 significzmtly increases 
the cndot.oxin-induced TNF lcvcls in the strum, liver 
and spleen and the drug wn induct TNF syrlthcsis in 
mycloid cells. even in the clbscncc of cndotoxin. Thcsc 
observations explain tlx shock-sensitizing cffcct of this 
compound, and suggest the invoivcmcnt of endogcnous 
‘rilblc I 




(1) TNP 20120 100 
(2) LPS 20/10 IOU 
(3) TNF+LPS 16120 80 3 vs. I NS 
(4) TNF+Rll I4420 70 4 vs, I P < 0.05 
(5) LPS+RU 201’0 100 5 vs. 2 PIS 
(6) TNF+LPS+RU O/20 0 6 vs. 3 P < 0.001 
(7) TNF+LPS+RU+MP lJ!?O 70 1 vs. 6 P * 0.001 
Animals wrc yivcll Li’S (1 FE’s). TNF (Z&t/lo I). RU 3X-W (1 W) 
;utd hip (2 nrp) itttr:~vcnousI~. Numhr5 of sur+ors wcrc rccordcd 
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glucosorticoids in the regulation of TNF expression. 
RU 38486 acts on the receptor lcvcl, und thus the in- 
creased TNF production seems EO bc mediated via the 
glucocorticoid receptors. This is corroborated by the 
observation that mcthylprcdnisolonc complctciy abal- 
ishcd the cffcct of RU 38486 on the production of TNF, 
Our experiments revealed that RU 38436 enhances 
the toxic effects of hTNF in both cell cultures and cxpcr- 
imcntal nnimals. It increases the expression of the TNF 
gene in cells producing TNF and simultaneously de= 
creases the tolcrancc of cells to TNF by interfering with 
the protcctivc cffsct of cndogcnous glusasorticoids. A
recent rcccptor [29] dcmonstrntcd that TNF c~uscs 
abortion in pregnant mice and destroys embryonic ells 
in combination with IFN-r. It is conccivablc that. in 
addition to its action as an antiprogcstcronc, the in= 
creased susceptibility of the fcttli tissues to cndogcnous 
TNF may also play o role in the abortogsnic effect of 
mifcpristonc. 
Our results concerning the effect of the new glucocor- 
ticoid antagonist on systemic TNF production and tox- 
icity confirmed the important role cndogsnous gluco- 
corticoids play in the control of the immunopathologi- 
col proscsscs caused by high lcvcls of certain lympho- 
kincs. 
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